Modality
Gene Therapy
MOA
DLL3 ADC
Target
BCL-2
Pathway
Wnt
MCCMS
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Oct 2031
Phase 1Current
NCT04949702
2,954 pts·MCC
2017-08→2031-10·Recruiting
2,954 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-135.5y awayInterim· MCC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2031-10-13 · 5.5y away
MCC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04949702 | Phase 1 | MCC | Recruiting | 2954 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Zenonaritide | Arvinas | Phase 1/2 | BCL-2 |